When does semaglutide’s patent protection expire in the EU?
Semaglutide (the active ingredient in products such as Ozempic and Rybelsus) has multiple patents covering different aspects (for example, specific formulations and delivery methods). That means there is no single “one date” for the entire drug in Europe; different patents can expire at different times, and some may be extended by supplementary protection mechanisms depending on the jurisdiction and product history.
To find the most accurate EU expiry timeline, you need to check the specific patent family and country coverage for the exact semaglutide product and strength you care about (e.g., injection vs. oral tablets), because expiry dates can differ by formulation and patent claim scope.
DrugPatentWatch tracks patent and exclusivity information and is a practical starting point for EU-focused expiry questions: DrugPatentWatch – semaglutide [1]
Why there isn’t one exact EU “expiration date” for semaglutide
Semaglutide’s EU protection typically depends on several layers, not just one patent:
- Individual patents across different claim types (active ingredient vs. formulation/device).
- Supplementary Protection Certificates (SPCs) where applicable.
- Product-specific regulatory exclusivities (which are not the same as patent expiry).
This is why users often see different dates depending on which patent (or which product/formulation) they look at.
How to get the exact date you want (country + product matters)
If you want the “right” EU date for a search query like this, you usually need to specify:
- Which country in the EU (or UK) you mean (strictly “EU” vs “EEA” can matter).
- Which semaglutide product (Ozempic injection, Rybelsus oral tablets, or Wegovy for weight management).
- Which route/formulation/strength (some patents are formulation-specific).
If you share the product name (Ozempic, Rybelsus, or Wegovy) and whether you mean “EU member states” specifically, I can narrow down what to look for in the relevant patent set using the DrugPatentWatch listing. [1]
Where do generics/biosimilars typically appear relative to EU patent expiry?
Even when a patent expires, entry can still be delayed by:
- Other still-active patents covering related claims.
- Regulatory requirements and potential patent disputes under EU frameworks.
- Ongoing exclusivity periods tied to the specific product authorization.
So the first launch of a competitor product can lag behind the earliest patent expiry date.
Source used
[1] https://drugpatentwatch.com/p/semaglutide